Medmark Elixir Llp - Due diligence report

A 360° intelligence report on Medmark Elixir Llp: trust score, financial health, credit view, compliance, directors, growth and distress sig…

2015-07-02 New Delhi, Delhi Active
Share
View plans Plan
ME Medmark Elixir Llp
View plans Plan
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Medmark Elixir Llp — 360° Intelligence Report

Generated from MCA filings & public records
83/100
Trust Score
Low Risk

Medmark Elixir Llp is assessed as Low Risk with a Trust Score of 83/100. Medmark Elixir Llp is an active limited liability partnership incorporated in 2015, operating in the Healthcare sector. Processed financial statements are not yet available for trend analysis. Based on MCA filings and public records, it currently shows a low compliance risk and an unassessed financial risk profile.

Report generated on 10 Jul 2026 from the latest processed filings. Medmark Elixir Llp snapshot & full profile →

Financial Health › No Data
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreNo Data
N/A
No processed financial statements available yet.
Credit Risk ScoreNo Data
N/A
Financial statements needed for a credit view.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreNo Data
N/A
Needs at least two filed years to measure growth.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

No processed financials
Financial statements are not yet processed for this company. Trend analysis will appear once filings are available.
04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: N/A No Data
  • Financial statements needed for a credit view.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2021 - filings overdue.
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MAHESH RAI 01234567 Director 01/04/2018 6 yrs Approved
PRATEEK SONI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth N/A · Distress 80
Growth signals & trust indicators
Operating for 11+ years.
Financials unavailable - score leans on compliance and governance signals.
Distress signals & risk flags
Statutory filings appear overdue.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • No financials on record - ask for audited statements.
Banker assessment70/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • No filed financials - rely on banking statements and GST data.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view63/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Request management accounts - public filings insufficient.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 7 events
31 Mar 2024
Last AGM held
Annual general meeting
31 Mar 2021
Latest balance sheet
Filed with ROC
07 May 2018
Director ceased
SUBHASH PASSI
01 Aug 2016
Director appointed
PRATEEK SONI (Designated Partner)
21 Dec 2015
Director ceased
ANUBHA RAI
02 Jul 2015
Incorporated
Registered with Roc Delhi
Director appointed
MAHESH RAI (Designated Partner)
10

Key Observations

Auto-generated from the data above
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
11

Peers & Related Companies

Full peer comparison →
Peer companies will appear here as our matching engine processes this industry.
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Medmark Elixir Llp before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Medmark Elixir Llp: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score pending financials, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score n/a, margin trends, ownership structure and peer set for Medmark Elixir Llp - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Medmark Elixir Llp pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Medmark Elixir Llp - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Medmark Elixir Llp an active company?

Medmark Elixir Llp has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Medmark Elixir Llp financially healthy?

Processed financial statements are not yet available for Medmark Elixir Llp, so its financial health is unassessed.

Should I do business with Medmark Elixir Llp?

Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Medmark Elixir Llp?

See the directors and ownership sections above for board and shareholding detail. 2 active director(s) are on record.

Does Medmark Elixir Llp have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Medmark Elixir Llp up to date with its ROC filings?

Last balance sheet is for Mar 2021 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Medmark Elixir Llp?

Filed financial statements are needed for a credit view - ask the company for audited statements and bank statements.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.